Impact of miRNAs on cardiovascular aging

Journal of Geriatric Cardiology

Volumn 12, Issue 5, 2015, Pages 569-574

  Lee, Seahyoung ^a   Choi, Eunhyun ^a   Cha, Min Ji ^a   Park, Ae Jun ^a   Yoon, Cheesoon ^a   Hwang, Ki Chul ^a  

^a Catholic Kwandong University   (South Korea)

Author keywords

Aging heart; Cardiovascular aging; MiRNA; Senescence; Vascular aging

Indexed keywords

MICRORNA; MICRORNA 125A 5P; MICRORNA 17 3P; MICRORNA 18; MICRORNA 19; MICRORNA 192; MICRORNA 22; MICRORNA 29; MICRORNA 34A; UNCLASSIFIED DRUG;

AGING; CARDIOVASCULAR DISEASE; HUMAN; NONHUMAN; REVIEW;

EID: 84944070283     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2015.05.011     Document Type: Review

References (68)

1. Cevenini E, Caruso C, Candore G, et al. Age-related inflammation: the contribution of different organs, tissues and systems. How to face it for therapeutic approaches. Curr Pharm Des 2010; 16: 609-618.
2. Lopez-Otin C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013; 153: 1194-1217.
3. Anton B, Vitetta L, Cortizo F, et al. Can we delay aging? The biology and science of aging. Ann N Y Acad Sci 2005; 1057: 525-535.
4. Corella D, Ordovas JM. Aging and cardiovascular diseases: The role of gene-diet interactions. Ageing Res Rev 2014; 18C: 53-73.
5. Liu FJ, Wen T, Liu L. MicroRNAs as a novel cellular senescence regulator. Ageing Res Rev 2012; 11: 41-50.
6. Gorospe M, Abdelmohsen K. MicroRegulators come of age in senescence. Trends Genet 2011; 27: 233-241.
7. Lanceta J, Prough RA, Liang R, et al. MicroRNA group disorganization in aging. Exp Gerontol 2010; 45: 269-278.
8. Inukai S, Slack F. MicroRNAs and the genetic network in aging. J Mol Biol 2013; 425: 3601-3608.
9. Dimmeler S, Nicotera P. MicroRNAs in age-related diseases. EMBO Mol Med 2013; 5: 180-190.
10. Zhuo R, Fu S, Li S, et al. Desregulated microRNAs in aging-related heart failure. Front Genet 2014; 5: 186.
11. Jung HJ, Suh Y. Circulating miRNAs in ageing and ageing-related diseases. J Genet Genomics 2014; 41: 465-472.
12. Harries LW. MicroRNAs as mediators of the ageing process. Genes (Basel) 2014; 5: 656-670.
13. Chen LH, Chiou GY, Chen YW, et al. MicroRNA and aging: a novel modulator in regulating the aging network. Ageing Res Rev 2010; 9 (SUPPL. 1): S59-S66.
14. Grigoriev A, Bonini NM. Age-dependent patterns of microRNA RISC loading. Aging (Albany NY) 2014; 6: 705-706.
15. Weilner S, Grillari-Voglauer R, Redl H, et al. The role of microRNAs in cellular senescence and age-related conditions of cartilage and bone. Acta Orthop 2015; 86: 92-99.
16. Mimura S, Iwama H, Kato K, et al. Profile of microRNAs associated with aging in rat liver. Int J Mol Med 2014; 34: 1065-1072.
17. Jung HJ, Suh Y. MicroRNA in aging: from discovery to biology. Curr Genomics 2012; 13: 548-557.
18. North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res 2012; 110: 1097-1108.
19. Zhang X, Azhar G, Wei JY. The expression of microRNA and microRNA clusters in the aging heart. PLoS One 2012; 7: e34688.
20. Agostini M, Knight RA. miR-34: from bench to bedside. Oncotarget 2014; 5: 872-881.
21. Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis 2014; 5: e1327.
22. Misso G, Di Martino MT, De Rosa G, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids 2014; 3: e194.
23. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-199.
24. Bader AG. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120.
25. Chiao YA. MicroRNA-34a: a new piece in the cardiac aging puzzle. Circ Cardiovasc Genet 2013; 6: 437-438.
26. Loffredo FS, Pancoast JR, Lee RT. Keep PNUTS in your heart. Circ Res 2013; 113: 97-99.
27. Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013; 495: 107-110.
28. Jazbutyte V, Fiedler J, Kneitz S, et al. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr) 2013; 35: 747-762.
29. Kampmann A, Fernandez B, Deindl E, et al. The proteoglycan osteoglycin/mimecan is correlated with arteriogenesis. Mol Cell Biochem 2009; 322: 15-23.
30. Zhou M, Cai J, Tang Y, et al. MiR-17-92 cluster is a novel regulatory gene of cardiac ischemic/reperfusion injury. Med Hypotheses 2013; 81: 108-110.
31. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
32. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006; 38: 1060-1065.
33. Suarez Y, Fernandez-Hernando C, Yu J, et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A 2008; 105: 14082-14087.
34. van Almen GC, Verhesen W, van Leeuwen RE, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011; 10: 769-779.
35. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 2013; 20: 1603-1614.
36. Olive V, Li Q, He L. mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev 2013; 253: 158-166.
37. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133: 217-222.
38. Chen J, Huang ZP, Seok HY, et al. mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res 2013; 112: 1557-1566.
39. Danielson LS, Park DS, Rotllan N, et al. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J 2013; 27: 1460-1467.
40. Du WW, Li X, Li T, et al. Expression of microRNA miR-17-3p inhibits mouse cardiac fibroblast senescence by targeting Par4. J Cell Sci 2015; 128: 293-304.
41. Burikhanov R, Zhao Y, Goswami A, et al. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009; 138: 377-388.
42. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 2003; 107: 139-146.
43. Jani B, Rajkumar C. Ageing and vascular ageing. Postgrad Med J 2006; 82: 357-362.
44. Ungvari Z, Kaley G, de Cabo R, et al. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 2010; 65: 1028-1041.
45. O'Rourke JR, Olson EN. Modulating the microRNA architecture of an aging aorta. Circ Res 2011; 109: 1098-1099.
46. van Leeuwen I, Lain S. Sirtuins and p53. Adv Cancer Res 2009; 102: 171-195.
47. Pillarisetti S. A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases. Recent Pat Cardiovasc Drug Discov 2008; 3: 156-164.
48. Alcendor RR, Gao S, Zhai P, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100: 1512-1521.
49. Chua KF, Mostoslavsky R, Lombard DB, et al. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab 2005; 2: 67-76.
50. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-2921.
51. Concepcion CP, Han YC, Mu P, et al. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet 2012; 8: e1002797.
52. Badi I, Burba I, Ruggeri C, et al. MicroRNA-34a induces vascular smooth muscle cells senescence by SIRT1 down-regulation and promotes the expression of age-associated pro-inflammatory secretory factors. J Gerontol A Biol Sci Med Sci 2014; doi:10.1093/gerona/glu180.
53. Kang SS, Kwon T, Kwon DY, et al. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999; 274: 13085-13090.
54. Scheid MP, Woodgett JR. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003; 546: 108-112.
55. Bellacosa A, Kumar CC, Di Cristofano A, et al. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
56. Zheng Y, Xu Z. MicroRNA-22 induces endothelial progenitor cell senescence by targeting AKT3. Cell Physiol Biochem 2014; 34: 1547-1555.
57. Boon RA, Seeger T, Heydt S, et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 2011; 109: 1115-1119.
58. Xu J, Shi GP. Vascular wall extracellular matrix proteins and vascular diseases. Biochim Biophys Acta 2014; 1842: 2106-2119.
59. Boon RA, Dimmeler S. MicroRNAs and aneurysm formation. Trends Cardiovasc Med 2011; 21: 172-177.
60. Kriegel AJ, Liu Y, Fang Y, et al. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44: 237-244.
61. Herrera MD, Mingorance C, Rodriguez-Rodriguez R, et al. Endothelial dysfunction and aging: an update. Ageing Res Rev 2010; 9: 142-152.
62. Che P, Liu J, Shan Z, et al. miR-125a-5p impairs endothelial cell angiogenesis in aging mice via RTEF-1 downregulation. Aging Cell 2014; 13: 926-934.
63. Vasa-Nicotera M, Chen H, Tucci P, et al. miR-146a is modulated in human endothelial cell with aging. Atherosclerosis 2011; 217: 326-330.
64. Touyz RM, Montezano AC. Vascular Nox4: a multifarious NADPH oxidase. Circ Res 2012; 110: 1159-1161.
65. Menghini R, Casagrande V, Cardellini M, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009; 120: 1524-1532.
66. Ota H, Akishita M, Eto M, et al. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007; 43: 571-579.
67. Potente M, Urbich C, Sasaki K, et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 2005; 115: 2382-2392.
68. Potente M, Ghaeni L, Baldessari D, et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007; 21: 2644-2658.